Innocan Pharma Corporation reported the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application and New Drug Application of Innocan's liposomal CBD drug product file following completion of toxicology, pharmacokinetics and efficacy studies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.31 CAD | -3.12% | +5.08% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 66.85M | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |
- Stock
- Equities
- Stock InnoCan Pharma Corporation - Canadian Securities Exchange
- News InnoCan Pharma Corporation
- InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform